Zerenex ferric citrate: Phase III data

Top-line data from the open-label, Japanese Phase III GBA4-1 trial in ESRD patients on hemodialysis with hyperphosphatemia showed that Zerenex was non-inferior to sevelamer hydrochloride on the primary endpoint of reducing serum phosphorus levels from baseline to week 12. Additionally, no clinically significant effects on safety and tolerability were reported. Japan Tobacco plans to submit a regulatory application in Japan for the product during its fiscal year ending March 31, 2013. ...